RB investor presentationHalf year 2016

29th July 2016

1

Rakesh KapoorChief executive officer

2

Disclaimer

Cautionary note concerning forward-looking statements• This presentation contains statements with respect to the financial condition, results of operations and business of RB (the “Group”)

and certain of the plans and objectives of the Group that are forward-looking statements. Words such as ‘intends’, ‘targets’, or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. In particular, all statements that express forecasts, expectations and projections with respect to future matters, including targets for net revenue, operating margin and cost efficiency, are forward-looking statements. Such statements are not historical facts, nor are they guarantees of future performance.

• By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements, including many factors outside the Group’s control. Among otherrisks and uncertainties, the material or principal factors which could cause actual results to differ materially are: the general economic, business, political and social conditions in the key markets in which the Group operates; the ability of the Group to manage regulatory, tax and legal matters, including changes thereto; the reliability of the Group’s technological infrastructure or that of third parties on which the Group relies; interruptions in the Group’s supply chain and disruptions to its production facilities; the reputation of the Group’s global brands; and the recruitment and retention of key management.

• These forward-looking statements speak only as of the date of this announcement. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

3

Key messages

Health and Hygiene

focus driving growth

Virtuous earnings

model delivering

Full year targetson track

4

Health, Hygiene, Home category growth trends have not changed materially

CAGR

Estimated medium term category growth trends – RB categories and markets

5

Health & Hygiene driving growth…

6

+8%*

+5%*

+10%*

=+Q1 Q2 H1

+5%*+7%*

+3%*

=+Q1 Q2 H1

Category growth CAGR Category growth CAGR

* RB NR LFL growth

Virtuous earnings model fully intact and delivering…

7

Grossmargin

Reinvestdrive

Netrevenuegrowth

Fixedcost

Operatingmargin

+240bps(Mix / project fuel / pricing / Supercharge)

+20bps

+180bps

+5% LFL

+40bps(+39m*)*at constant exchange rate

In summaryA strong start

8

Net revenue growth (LFL)

Net income growth

Cash conversion

>100%

+5% +12%*Interim

dividend58.2p

*Adjusted net income, at constant exchange rate

Adrian Hennah Chief financial officer

9

Q2 & HY 2016 resultsIncome statement

*Adjusted to exclude the impact of exceptional items

Q2 H12016 2015 2016 2015

£m £m £m £mRevenue 2,266 2,140 4,569 4,356LFL % 4% 5% 5% 5%

Gross margin 2,740 2,511Gross margin % 60.0% 57.6%

Adjusted operating profit* 1,081 953Adjusted operating profit %* 23.7% 21.9%

Exceptionals (319) (14)

Operating profit 762 939

10

HY 2016 results Income statement

H12016 2015£m £m

Operating profit 762 939

Net finance expense (11) (18)

Profit before taxation 751 921

Taxation (223) (212)

Tax rate – Adjusted 23% 18%

Tax rate 30% 19%

Non-controlling Interest (2) -

Net income 526 709

Adjusted net income* 822 720Diluted EPS 73.4p 97.5pAdjusted diluted EPS 114.7p 99.0p

*Adjusted to exclude the impact of exceptional items and their associated tax effect

11

LFL Revenue growth by QuarterBusiness Segment

2015 2016 Total NR

Q1 Q2 Q3 Q4 FY Q1 Q2 HY FY

£m

NA 3% 3% 5% 4% 3% 1% 3% 2% 1,048

Rest of ENA 5% 4% 7% 6% 6% 5% 1% 3% 1,881

ENA 4% 4% 6% 5% 5% 3% 2% 3% 2,929

DvM 6% 8% 10% 12% 9% 10% 8% 9% 1,457

Food 4% 1% 3% 8% 4% 2% 5% 4% 183

Group 5% 5% 7% 7% 6% 5% 4% 5% 4,569

12

Revenue growth by QuarterCategory

2015 2016 Total NR

Q1 Q2 Q3 Q4 FY Q1 Q2 HY FY

£m

Health 13% 13% 14% 14% 14% 10% 5% 8% 1,501

Hygiene 3% 3% 4% 4% 3% 3% 7% 5% 1,934

Home -1% 2% 5% 1% 2% 3% -1% 1% 834

Portfolio -3% -6% 5% 10% 1% 1% -8% -3% 300

Group 5% 5% 7% 7% 6% 5% 4% 5% 4,569

13

Margin Analysis

Gross Margin H1At actual % bps v PY

2016 60.0% +240bps2015 57.6% +90bps

BEI H1At actual % bps v PY

2016 14.8% +40bps2015 14.4% +30bps

Operating Margin H1At actual % bps v PY

2016 23.7% +180bps2015 21.9% +160bps

14

Profitability by business segment

Adjusted to exclude the impact of exceptional items

H1

2016%

2015%

ENA 25.5% 24.2%

DvM 20.0% 16.8%

FOOD 23.5% 25.6%

Group 23.7% 21.9%

15

Net Working Capital

16

NWCHY16 HY15 FY15

£m £m £m

Inventory 752 707 681% to last 12 month revenue 8% 8% 8%

Receivables 1,377 1,208 1,331% to last 12 month revenue 15% 14% 15%

Payables (3,400) (2,948) (2,948)% to last 12 month revenue -37% -33% -33%

Net working capital (1,271) (1,033) (936)% to last 12 month revenue -14% -12% -11%

Free cash flow

17

H1 FY2016 2015 2015

£m £m £m

Adjusted Operating Profit* 1,081 953 2,374Share based payment 33 25 50Depreciation and amortisation 83 85 171Net Capital expenditure (260) (76) (168)Movement in net working capital 286 125 (79)Movement in provisions and other creditors (20) (73) (50)Other non-cash movements in operating profit - (2) (33)Trading cashflow 1,203 1,037 2,265

Exceptional cashflow (14) (62) (98)

Operating Cashflow 1,189 975 2,167

Net interest paid (8) (17) (31)Taxation paid (242) (202) (480)Free Cashflow 939 756 1,656

Free Cashflow as % of Adjusted Net Income 114% 105% 89%

Closing net debt (1,578) (1,793) (1,620)

* Adjusted to exclude the impact of exceptional items

Korea ‘HS’ Issue

18

Korea HS Timeline

19

2000 2001 2011 2012

c.2000Oxy, an independent Korean manufacturer of household

goods, reformulates Humidifier Sanitiser (HS)

to include PHMG

March 2001RB acquires Oxy

August 2011KCDC* announces link

between HS products and severe respiratory disease

RB withdrawsHS product from market

November 2012KCDC* Committee formed

to review all reported cases of injury

HS product less than 0.5% of total RB Korea sales

2000-2011

* Korean Centre for Disease Control

KCDC Assessments

20

Round Total applicants Category I &II RB Oxy users – cat I &II Completion dateactual/target

1 361 172 136 Nov 12

2 169 49 45 Oct 14

3 752

To be determined

Dec 15

4 TBD* Open

* No numbers published for Round 4

Korea HS Timeline

21

2012 2014 2016

2014Oxy RB found liable

of civil offence of mislabelling; fined

2016Prosecutor brings criminal charges

against multiple defendants

Q2 2016Oxy RB undertakes consultation on a

Compensation Plan for Round 1&2/Category I&II victims

2014 - Q1 201680% of civil cases brought by victims settled through Court mediation

Korea – Financials

22

Impact on trading

Exceptional costs

Contingent liabilities

Rakesh KapoorChief executive officer

23

New initiatives for H2 2016

24

2525

Scholl® Light Legs

Scholl® Light Legs Compression TightsFor legs that feel great and look great – all day long

Amope® GelActiv Insoles & Inserts

Amope® GelActiv Insoles & InsertsInvisible gel insoles and inserts for all types of female shoes

Superior all day comfort for tired and achy feet

Mega Red® Advanced 4-in-1

Mega Red® Advanced 4-in-1Our strongest Omega-3 supplement. 2X more concentrated Omega-3s vs. standard fish oil

Nurofen® up to 8 Hour Relief range

Nurofen® up to 8 Hour ReliefProvides longer lasting pain relief for up to 8 hours with just one single dose

Available in tablets, patches and gel formats

Mucinex® Clear & Cool

Mucinex® Clear & Cool Clears congestion. Cools with an instant menthol burst!

30

Optrex® Night Repair Gel Drops

31

Optrex® Night Repair Gel DropsRestores & repairs your eyes while you sleep

Durex® Intense Orgasm Gel & Condom

Durex® Intense Orgasm Gel & CondomJust a few drops of Durex Intense Gel together with the new Durex Intense Condom, to

protect and pleasure even more!

3333

Veet® Sensitive Precision

Veet® Sensitive Precision Beauty StylerGentleness & precision for sensitive body areas

34

Dettol® On-The-Go Sanitiser

Dettol® On-The-Go Hand SanitiserOffering germ protection in an easy to carry format anytime, anywhere!

35

Harpic® Bathroom Cleaner

Harpic® Bathroom CleanerFor a perfectly clean & sparkling bathroom

36

3737

Air Wick® Pure Essential Oils

Air Wick® Pure Essential Oils FragranceJust fragrance, no wet spray.

Now available with fragrances containing 5 Essential Oils

38

Vanish® Gold

39

Vanish® Gold Now works even on 7 day dried-in stains!

2016 Targets

40

2016: Targets - LFL Net Revenue Target reaffirmed

41

Original

+4-5%

New

+4-5%Lower end

2016: Targets - operating margin*

42

Original

Moderate+

year 2 ofSupercharge

NewH1

+180bps

H2Moderate expansion

+

*Adjusted to exclude the impact of exceptional items

Q&A

43

Appendices

44

Analysis of Exceptional costs

45

Total P&L Total P&L Total cash

Guidance HY 2016 to date to date

£m £m £m £m

Acquisition, integration and restructuring 390 19 244 189

Litigation provisions 210 - 210 142

Korea “HS” 300 300 300 7

Reconciliation of Operating Profit to AdjustedOperating Profit

46

HY HY2016 2015

£m £m

Operating profit 762 939

Adjusting items:Korea HS issue 300 -Acquisition, integration and restructuring 19 14

Adjusted operating profit 1,081 953

Revenue growth by Business segment Q2 2016

47

LFL Acq/Disp FX Reported

% % % %

North America 3% - 6% 9%

Rest of ENA 1% -2% 4% 3%

Total ENA 2% -1% 4% 5%

DvM 8% - -1% 6%

FOOD 5% - 6% 10%

Group 4% -1% 3% 6%

Due to rounding this table will not always cast

Revenue growth by Business segment H1 2016

48

LFL Acq/Disp FX Reported

% % % %

North America 2% 0% 6% 7%

Rest of ENA 3% -2% 2% 4%

Total ENA 3% -1% 3% 5%

DvM 9% 0% -4% 4%

FOOD 4% 0% 5% 9%

Group 5% -1% 1% 5%

Due to rounding this table will not always cast

Reconciliation in net debt

49

2016£m

Opening net debt (1,620)Free cashflow 939Shares purchased (400)Shares reissued 61Purchase of businesses (42)Dividends paid (625)Exchange and other movements 109

Closing net debt (1,578)